|
Daily Medical Update
Bladder carcinoma
Tuesday, July 14, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The French journal of urology (2025) - Practice Guideline
Key Findings
- The 2025 update increased recommended use of BCG plus systemic immunotherapy in high-risk NMIBC and BCG-endovesical therapy sections.
- For MIBC, the update increased perioperative chemotherapy-immunotherapy recommendations across neoadjuvant cisplatin-based and adjuvant immunotherapy treatment pathways.
📋 Practice Implication: Use the updated AFU pathway as a checkpoint when reviewing high-risk NMIBC and MIBC plans, especially where immunotherapy combinations may change sequencing.
|
European urology oncology (2025) - Network Meta-Analysis
Key Findings
- ICI-chemotherapy combinations increased pathologic complete response versus chemotherapy alone, 40.6% vs 17.9% (p < 0.01).
- Durvalumab plus gemcitabine-cisplatin showed no overall survival difference versus ddMVAC in phase 3 RCT data (HR 1.06, 95% CI 0.72-1.55; p = 0.8).
📋 Practice Implication: Consider neoadjuvant ICI-chemo as a response-enhancing option in selected MIBC patients, but do not assume survival superiority over established cisplatin regimens.
|
JAMA network open (2026) - Network Meta-Analysis
Key Findings
- Enfortumab vedotin monotherapy produced pooled objective response rates of 43.9% in interventional studies and 44.6% in observational cohorts.
- Enfortumab vedotin plus pembrolizumab increased pooled objective response to 67.5% overall and 65.4% among cisplatin-ineligible patients.
📋 Practice Implication: For la/mUC, response expectations should be regimen-specific; EV-pembrolizumab data support early combination consideration, particularly when cisplatin is unsuitable.
|
Urologic oncology (2026) - Network Meta-Analysis
Key Findings
- Across 37 studies and 7,388 patients, urinary tumor DNA showed pooled sensitivity of 79% (95% CI 73%-84%) and specificity of 86% (95% CI 83%-89%).
- Urinary tumor DNA had over 4-fold higher sensitivity than urine cytology, while NGS-based assays improved sensitivity versus methylation-based assays (0.83 vs 0.75; p = 0.01).
📋 Practice Implication: utDNA can be discussed as an adjunct for detection or surveillance when cystoscopy burden is high, but implementation and cost-effectiveness remain unresolved.
|
International journal of molecular sciences (2026) - Meta-Analysis
Key Findings
- The pooled prevalence of FGFR3 alterations was 52% (95% CI 23.33%-80.12%; I2 = 99%) across 14 studies including 3,955 patients.
- Nectin-4 expression was 78% (95% CI 64.23%-89.81%; I2 = 91%), with FGFR3 prevalence increasing in advanced or metastatic disease and randomized trial cohorts (p < 0.05).
📋 Practice Implication: Order and interpret FGFR3 and Nectin-4 testing with attention to assay and cohort context, using positive results to guide targeted therapy and ADC eligibility discussions.
|
|
💡
Summary
Recent bladder carcinoma evidence emphasizes treatment intensification and better selection: perioperative immunotherapy combinations are entering guideline pathways, ADC combinations show high response rates in advanced disease, and neoadjuvant ICI-chemotherapy improves pathologic complete response in MIBC. Diagnostic and biomarker evidence also supports selective use of urinary tumor DNA and routine molecular profiling, while noting heterogeneity that should temper overinterpretation.
|
|